PUBLISHER: Allied Market Research | PRODUCT CODE: 1641728
PUBLISHER: Allied Market Research | PRODUCT CODE: 1641728
The cytogenetics market was valued at $2,809.40 million in 2023 and is estimated to reach $10,627.05 million by 2035, exhibiting a CAGR of 11.7% from 2024 to 2035.
Cytogenetics is a branch of genetics focused on the study of chromosomes, the structures within cells that contain DNA. It involves analyzing the number, structure, and behavior of chromosomes to understand their role in heredity, disease, and biological function. Techniques in cytogenetics, such as karyotyping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH), allow scientists to identify chromosomal abnormalities, such as deletions, duplications, translocations, and aneuploidies. These abnormalities are linked to various genetic disorders, cancers, and congenital conditions. By examining the chromosomal makeup of cells, cytogenetics plays a crucial role in prenatal diagnosis, cancer research, genetic counseling, and personalized medicine. The field bridges classical genetics with modern molecular biology, offering insights into how changes at the chromosomal level can affect an individual's health and development, making it an essential tool in both clinical and research settings.
The major factors that drive the growth of cytogenetics market include the rise in prevalence of genetic disorders and cancer globally which fuels demand for cytogenetic testing and diagnostics. As genetic conditions such as Down syndrome, and various types of cancer become more prevalent, the need for accurate and early detection methods has grown significantly. Cytogenetic techniques, including karyotyping, fluorescence in situ hybridization (FISH), and chromosomal microarray analysis (CMA), are essential for identifying chromosomal abnormalities associated with these conditions, thereby driving market growth.
However, the high cost associated with cytogenetic technologies, including equipment, and specialized expertise can be prohibitive, particularly in low- and middle-income countries, limiting access to advanced diagnostic tools and limiting the market growth. In addition, the complexity of cytogenetic procedures requires skilled professionals and specialized training, which can be scarce in certain regions, further constraining market growth. On the other hand, increase in demand for personalized medicine, which relies heavily on advanced genetic testing to tailor treatments to individual patients' genetic profiles and high growth potential in emerging countries create an opportunity for market expansion.
Cytogenetics market is categorized into product, technique, application, end user, and region. On the basis of the product, it is segmented into consumable, instrument, and software & service. The consumables segment is further classified into testing kits and reagents, media, probes, and others. Media segment further includes serum media and others. On the basis of technique, the market is segmented into comparative genome hybridization, fluorescence in situ hybridization, karyotyping, and others. The karyotyping segment further categorized into prenatal testing, cancer, and others. Prenatal testing segment categorized into consumable, instrument, and software & services. Cancer segment further categorized into consumables which includes testing kits and reagents and media. Others segment also categorized into consumables which includes testing kits and reagents and media.
On the basis of application, it is segmented into genetic disorders, cancer, personalized medicine, and others. On the basis of end user, the market is classified into clinical and research laboratory, pharmaceutical and biotechnology company, academic research institute, and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA).
The major companies profiled in the report include PAN-Biotech, Precipio, Inc., Applied Spectral Imaging, Capricorn Scientific, AddLife, and Thermo Fisher Scientific Inc. The key players operating in the market have adopted partnership, joint venture, collaboration, and agreement as their key strategy to expand their product portfolio. For instance, in January 2024, Barco and Applied Spectral Imaging (ASI), a world leader in advanced biomedical imaging with a comprehensive product portfolio for karyotyping, H&E, IHC and FISH imaging and analysis, announced a new commercial partnership to offer best-in-class digital solutions for pathology laboratories
Key Benefits for Stakeholders
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
◦ Type
◦ Type
◦ Consumables
◦ Consumable